iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments.

iCAD, Inc. ( NASDAQ:ICAD ) is possibly approaching a major achievement in its business, so we would like to shine some... iCAD ( NASDAQ:ICAD ) Full Year 2024 Results Key Financial Results Revenue ...

Brown noted that 2024 marked significant AI adoption in healthcare, with iCAD's solutions gaining traction due to their clinical efficiency and diagnostic accuracy improvements. ProFound Detection ...

Shares of iCAD stock opened at $2.24 on Friday. The firm has a market capitalization of $59.45 million, a PE ratio of -17.23 and a beta of 1.95. The business’s 50-day moving average price is $2. ...

ICAD ($ICAD) is expected to release its quarterly earnings data on Wednesday, March 19th after market close, per Finnhub. Analysts are expecting revenue of $4,924,050 ...

ICAD will support NIA with the systems integration design, integration programme management and integration of ICT and airport systems. It will also lead the core airport systems implementation ...

"iCAD’s partnership with RamSoft marks an important ... offers a flexible, scalable design enabling imaging operations of all sizes to leverage comprehensive cloud-based RIS (Radiology ...

Net Cash Used for Operating Activities: $3.9 million for the full-year 2024. ICAD Inc (NASDAQ:ICAD) reported strong revenue growth, with Q4 2024 revenue reaching $5.4 million, a 14% increase over ...